Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-23T15:42:25.031Z Has data issue: false hasContentIssue false

P01-153 - Effect of Pregabalin on Patients with Refractory-severe Generalized Anxiety Disorder and Concomitant Severe Symptoms of Depression in Daily Medical Practice

Published online by Cambridge University Press:  17 April 2020

J.M. Olivares
Affiliation:
Department of Psychiatry, Hospital Meixoeiro, Complejo Hospitalario Universitario, Vigo
J.L. Carrasco
Affiliation:
Department of Psychiatry, Hospital Clínico San Carlos, Madrid, Spain
E. Álvarez
Affiliation:
Department of Psychiatry, Hospital de la Santa Creu i San Pau, Barcelona, Spain
M. Perez
Affiliation:
Department of Neuroscience, Medical Unit, Pfizer Spain, Alcobendas (Madrid), Spain
V. López-Gómez
Affiliation:
Department of Neuroscience, Medical Unit, Pfizer Spain, Alcobendas (Madrid), Spain
I. Vilardaga
Affiliation:
Department of Biometric and Statistic, European Biometric Institute, Barcelona, Spain
J. Rejas
Affiliation:
Health Outcomes Research Department, Medical Unit, Pfizer Spain, Alcobendas (Madrid), Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Purpose

To analyse the effect of Pregabalin (PGB) on anxiety and depression symptoms in patients with refractory-severe Generalized Anxiety Disorder (GAD) and severe concomitant depressive disorder.

Methods

Post-hoc analysis of a multicentre, prospective and observational study conducted in outpatient psychiatric clinics to ascertain the impact of broadening GAD criteria. Men and women above 18 years, with GAD (DSM-IV criteria), PGB naïve and refractory to a previous course of benzodiazepines and/or anti-depressive drugs (minimum 3 months) and severe symptoms of anxiety (HAM-A ≥ 24) and depression (MADRS ≥ 35) were included. Changes in HAM-A and MADRS were assessed after 6 months of receiving PGB as per psychiatrist's judgement.

Results

159 patients [69.2% women, 45.9 (12.6) years] fulfilled criteria for analysis. Respectively, 92% and 90% of subjects were previously exposed to benzodiazepines and anti-depressives before adding PGB [mean dose: 223.1 (126.3) mg/day]. PGB therapy reduced both anxiety and depressive baseline symptoms by a mean of, respectively in HAM-A and MADRS scales, 57.9% (from 35.5±5.8 to 14.8±9.4; p< 0.001, effect size: 3.57) and 58.1% (from 39.4±4.3 to 16.5±10.3; p< 0.001, effect size: 5.33). As a result, the percentages of patients without symptoms of both anxiety and depression were 34.4% and 40.9%, respectively at the 6 month visit (p< 0.001 in all cases). Similarly, responder rates (≥ 50% reduction of baseline scoring) were 63.1% and 62.9%.

Conclusion

Despite limitations, Pregabalin therapy had a meaningful and significant effect of symptoms of anxiety and depression in patients with severe refractory GAD and concomitant severe depressive disorder.

Type
Anxiety disorders
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.